Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca ( (AZN) ) has shared an update.
On October 13, 2025, AstraZeneca announced a historic agreement with the US Government to lower the cost of prescription medicines for American patients. This agreement includes measures such as providing Direct-to-Consumer sales at significant discounts and participating in a direct purchasing platform. AstraZeneca will invest $50 billion in US manufacturing and R&D, aiming to generate $80 billion in total revenue by 2030, with 50% expected from the US. The agreement also involves delaying tariffs to support domestic manufacturing, reflecting AstraZeneca’s commitment to the US market and its role in biopharmaceutical innovation.
The most recent analyst rating on (AZN) stock is a Buy with a $101.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
AstraZeneca’s strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. The technical analysis suggests a bullish trend, though caution is advised due to potential overbought conditions. The high P/E ratio indicates a premium valuation, which may limit upside potential.
To see Spark’s full report on AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK. It focuses on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are sold in more than 125 countries and are used by millions of patients worldwide.
Average Trading Volume: 5,003,981
Technical Sentiment Signal: Buy
Current Market Cap: $264.4B
Learn more about AZN stock on TipRanks’ Stock Analysis page.